文献速递神经免疫

不同年代诊断的多发性硬化患者中复发相关与复发无关因素对总体扩展残疾状态量表进展的贡献

Relapse-Associated and Relapse-Independent Contribution to Overall Expanded Disability Status Scale Progression in Multiple Sclerosis Patients Diagnosed in Different Eras.
PubMed 文献 · Ann Neurol · 2024-10-09

该回顾性研究纳入1980至2022年在意大利蒙蒂基亚里多发性硬化中心诊断的1405例复发缓解型多发性硬化患者,比较不同诊断年代复发相关恶化与复发无关进展对扩展残疾状态量表进展的相对贡献。结果显示,近期诊断患者中两者均减少,但复发无关进展的贡献显著增加。

要点

  • 研究纳入1405例患者,按诊断年代分为1980-1996年、1997-2008年和2008年后三组。
  • 复发无关进展对总体扩展残疾状态量表进展的平均贡献在1980-1996年为78%,1997-2008年为76%,2008年后为87%(p=0.0009)。
  • 近期诊断患者中复发相关恶化和复发无关进展均较早期减少。

核心结论

  • 多发性硬化病程的减缓不仅由复发相关恶化事件减少决定,也由复发无关进展减少决定。
  • 进展向主要不依赖复发的形式转变,凸显了评估新疗法对复发无关进展效果的重要性。

研究设计与样本

  • 回顾性研究,纳入1980至2022年在意大利蒙蒂基亚里多发性硬化中心诊断的复发缓解型多发性硬化患者1405例。
  • 患者按诊断年代分为三组:1980-1996年诊断231例,1997-2008年诊断577例,2008年后诊断597例。
  • 通过从总体扩展残疾状态量表变化中扣除所有与复发相关的扩展残疾状态量表变化来分离复发无关进展。
  • 使用混合效应模型比较不同时期诊断患者中复发无关进展和复发相关恶化对扩展残疾状态量表进展的相对贡献。

主要发现

  • 在各年龄段,近期诊断患者中复发无关进展和复发相关恶化均较早期诊断患者减少。
  • 复发无关进展对总体扩展残疾状态量表进展的平均贡献在1980-1996年诊断患者中为78%,在1997-2008年诊断患者中为76%,在2008年后诊断患者中显著增加至87%(p=0.0009)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The introduction of disease-modifying therapies for multiple sclerosis (MS) has led to a deceleration of disease course over the years. Although decreased relapse rate constitutes a factor, the role of relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) in MS course deceleration is still unclear. METHODS: We retrospectively examined long-term Expanded Disability Status Scale (EDSS) progression in patients referred to the MS Center of Montichiari (Italy) and diagnosed with relapsing-remitting MS from 1980 to 2022. To isolate PIRA, we deducted all EDSS changes associated with relapses from overall EDSS change. We compared the relative contribution of PIRA and RAW to EDSS progression in patients diagnosed in different periods using mixed-effects models. RESULTS: A total of 1,405 patients were included in the study, of whom 231 were diagnosed in 1980-1996 (pre-treatment era), 577 in 1997-2008 (injectable disease-modifying therapy era), and 597 after 2008 (oral drugs, monoclonal antibodies, and anti-CD20 era). Across ages, both PIRA and RAW were reduced in patients diagnosed in more recent periods as compared with earlier periods. The average contribution of PIRA to overall EDSS progression was already predominant in patients diagnosed in 1980-1996 (78%) and in 1997-2008 (76%), but it was significantly increased (p = 0.0009) in patients diagnosed in later years (87%). INTERPRETATION: The deceleration of MS course observed throughout the years is determined not only by fewer RAW events, but also by a reduction in PIRA. However, the shift toward a mostly relapse-independent progression highlights the importance of evaluating new therapies based on their effect on PIRA. ANN NEUROL 2025;97:95-103.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Montobbio N, Cordioli C, Signori A, et al. Relapse-Associated and Relapse-Independent Contribution to Overall Expanded Disability Status Scale Progression in Multiple Sclerosis Patients Diagnosed in Different Eras. Ann Neurol. 2024. PMID: 39381962. doi:10.1002/ana.27093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。